TUSTIN, Calif., Oct. 3 /PRNewswire-FirstCall/ --
(http://www.amdl.com/) AMDL, Inc. (AMEX:ADL), a leading vertically integrated bio-pharmaceutical company with major operations in China and the US, today announced that the Company will present at the Maxim Group Growth Investor Conference in New York City on Tuesday, October 7, 2008 at 10:30 a.m. ET. AMDL's presentation will be held at the Grand Hyatt New York Hotel in the Morosco Room.
The Maxim Group Growth Conference features interactive presentations and one-on-one meetings with executives from over 80 emerging growth companies within various sectors including healthcare and pharmaceuticals. Attendees include securities analysts, fund managers and institutional investors.
AMDL, Inc. is a specialty pharmaceutical Company devoted to the research, development, manufacturing, and marketing of over 180 diagnostic, pharmaceutical, nutritional supplement, and cosmetic products in China and outlying markets.
This year alone, the Company has secured over $25 million in sales contracts for its best-selling Goodnak(R) anti-aging product; expanded the Goodnak(R) revenue opportunity with the launch of two additional product formulations that include Goodnak(R) capsules and Goodnak(R) lotions; and secured US FDA clearance on July 3, 2008 for its ELISA DR-70(R) FDP cancer diagnostic test - the first test to be cleared by the US FDA in over 25 years for the monitoring of colorectal cancer.
These are a few milestones AMDL's Board Chairman and Audit Committee Chair Mr. Douglas MacLellan will highlight in a presentation which will also cover AMDL's market opportunity as an aggressively growing micro-cap investment opportunity in the China specialty pharmaceuticals sector. He will also provide insight on AMDL's growth strategy, product portfolio and 2008 financial projections. The presentation will be live-broadcast over the Internet and archived for 90 days. Interested parties may listen to the presentation by visiting the Investor Information section of the Company's website at: http://www.amdl.com/ .
About AMDL:
Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs approximately 320 people in the U.S. and China. The Company has an additional 4 pharmaceutical and diagnostic products under review by various regulatory authorities.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management.
AMDL Contact:
Kristine Szarkowitz
Director-Investor Relations
(M) (206) 310-5323
DATASOURCE: AMDL, Inc.
CONTACT: Kristine Szarkowitz, Director-Investor Relations of AMDL,
+1-206-310-5323,
Web site: http://www.amdl.com/